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Abstract
Background: Lipid metabolism in mammals is orchestrated by a family of transcription factors called sterol regulatory
element-binding proteins (SREBPs) that control the expression of genes required for the uptake and synthesis of cholesterol,
fatty acids, and triglycerides. SREBPs are thus essential for insulin-induced lipogenesis and for cellular membrane
homeostasis and biogenesis. Although multiple players have been identified that control the expression and activation of
SREBPs, gaps remain in our understanding of how SREBPs are coordinated with other physiological pathways.
Methodology: To identify novel regulators of SREBPs, we performed a genome-wide cDNA over-expression screen to
identify proteins that might modulate the transcription of a luciferase gene driven from an SREBP–specific promoter. The
results were verified through secondary biological assays and expression data were analyzed by a novel application of the
Gene Set Enrichment Analysis (GSEA) method.
Conclusions/Significance: We screened 10,000 different cDNAs and identified a number of genes and pathways that have
previously not been implicated in SREBP control and cellular cholesterol homeostasis. These findings further our
understanding of lipid biology and should lead to new insights into lipid associated disorders.
Citation: Chatterjee S, Szustakowski JD, Nanguneri NR, Mickanin C, Labow MA, et al. (2009) Identification of Novel Genes and Pathways Regulating SREBP
Transcriptional Activity. PLoS ONE 4(4): e5197. doi:10.1371/journal.pone.0005197
Editor: Aimin Xu, University of Hong Kong, China
Received November 18, 2008; Accepted February 5, 2009; Published April 21, 2009
Copyright:  2009 Chatterjee et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was funded by an Ara Parseghian Medical Research Foundation grant (which went solely towards funding the post doctoral researcher and
first author, Sandipan Chatterjee) and by the Novartis Institutes for Biomedical Research. Novartis Institutes for Biomedical Research played an active role in study
design, data collection and analysis, decision to publish as well in preparing the manuscript.
Competing Interests: We have a patent filed relating to some of the material that is presented in the manuscript: (WO/2007/141346) GENES REGULATING
INTRACELLULAR CHOLESTEROL TRAFFICKING AS TARGETS FOR TREATMENT OF CHOLESTEROL-RELATED DISEASES. SC, JDS, NRM, CM, MAL and RS are employed
by Novartis.
* E-mail: devk@tcd.ie (KKD); rajeev.sivasankaran@novartis.com (RS)
¤a Current address: 3-V Biosciences, Schlieren, Switzerland
¤b Current address: Molecular Neuropharmacology, Department of Physiology, Trinity College Institute of Neuroscience, Dublin, Ireland
Introduction
Disruption of intracellular cholesterol metabolism and traffick-
ing is the primary cause of numerous human disorders [1]. It has
been shown that the sterol regulatory element binding protein
(SREBP) pathway is the master regulator of intracellular lipid
homeostasis [2,3]. SREBPs are generated from two genes,
SREBF1 and SREBF2, that are transcribed to form a number
of different mRNA and protein species [4–8]. The prevalent
isoforms are SREBP-1a, SREBP-1c and SREBP-2 [9,10], but
additional splice versions have been described [4,5,7,11,12].
SREBP-1a and SREBP-1c are both transcribed from the SREBF1
gene and differ in their first and last two exons, while SREBP-2 is
the predominant protein produced from the SREBF2 gene [8,13].
SREBPs are synthesized as inactive precursors that are
anchored in the membrane of the ER through two transmem-
brane domains [14]. The N-terminal domain contain motifs
required for dimerization, DNA binding and transactivation
[15,16]. The C-terminal domain of SREBP precursors mediates
the formation of complexes with SREBP cleavage-activating
protein (SCAP) [17], a membrane protein important for SREBP
stability and regulation [18–22]. Interaction of SCAP with the
COPII machinery leads to the incorporation of the SCAP/SREBP
complex into vesicles and transport to the Golgi [20,23–25].
SREBPs are then cleaved by Site-1 and Site-2 proteases (S1P and
S2P), leading to the transfer of active transcription factors to the
nucleus [26–29]. Here, SREBP dimers bind to sterol regulatory
elements (SRE) which are present in the promoter regions of genes
such as low-density lipoprotein receptor (LDL-R), 3-hydroxy-3-
methylglutaryl Coenzyme A reductase (HMGCR), and fatty acid
synthase, and multiple other genes involved in the regulation of
intracellular lipid metabolism [30,31]. Thus, regulation of SREBP
cleavage and activity is vital for cellular lipid homeostasis and cell
survival.
Studies with CHO cells and mice expressing dominant positive
versions of SREBPs have shown that the target genes of SREBP-
1a and SREBP-2 are largely overlapping. However, SREBP-1a is
somewhat more potent at activating genes involved in fatty acid
synthesis while SREBP-2 has a preference for genes involved in the
biosynthesis of cholesterol. The LDL receptor is controlled equally
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by both transcription factors [30,31,32]. SREBP-1c also controls
fatty acid-raising genes and, although significantly weaker than
SREBP-1a [30,32], it is the predominant SREBP isoform in many
tissues and in liver regulates the conversion of carbohydrates to
triacylglycerol in response to insulin [33].
SREBP-1a and SREBP-2 are subject to negative feedback
regulation by cholesterol [34]. Upon binding to cholesterol SCAP
undergoes a conformational change that triggers its interaction
with one of two ER membrane proteins termed insulin-induced
gene(INSIG)-1 and INSIG2 [21,35–40]. Under these circum-
stances SCAP dissociates from COPII, the SCAP/SREBP
complex remains in the ER, and proteolytic activation is blocked
[41,42]. In another feedback loop SREBP-1a and SREBP-1c are
suppressed by polyunsaturated fatty acids (PUFA) [43–45].
SREBP-1c transcription in the liver is controlled by liver X
receptors (LXR), whose activation in turn is blocked by PUFA
[43,46].
In spite of the current research efforts in this field, our
knowledge of intracellular cholesterol trafficking and homeostasis
is far from complete. To gain a better handle on these events, we
performed a genome-wide cDNA over-expression screen to
identify modulators of SREBP activity. We used a cell-based
luciferase assay that measures expression from an SREBP-specific
promoter. We also performed secondary biological assays to
further validate these hits. Additionally, employing a novel
modification of Gene Set Enrichment Analysis (GSEA) we
performed a pathway analysis on the high throughput screening
data, as GSEA was originally developed for analyzing microarray
experiments [47]. GSEA applies a priori biological knowledge to
genome-scale data sets to implicate pathways in the biological
system of interest [47]. In addition to known pathways regulating
lipid metabolism, such as the SREBP and nuclear hormone
receptor pathway, our analysis has led to the identification of a
number of pathways previously not associated with the regulation
of cellular cholesterol homeostasis. The data suggests that
pathways involved in intracellular signal transduction such as
tyrosine kinase signaling, G-protein / small GTPase pathways and
ephrin signaling positively affect intracellular cholesterol homeo-
stasis, while pathways acting at the extracellular level, such as
matrix proteins, cell-matrix and cell-adhesion proteins, and
pathways involved in cell structure and organization, negatively
regulate cellular cholesterol homeostasis.
We have validated the results of the primary screen through a
series of secondary biological assays and find considerable overlap
between the genes identified by secondary screening and the
pathways identified via GSEA, indicating that pathway-centric
analyses of biological screening data is a valid approach that may
assist in target identification. Our results implicate multiple novel
genes and pathways in intracellular cholesterol homeostasis and
open up novel venues for the interrogation of lipid biology and
lipid-linked disease.
Results
Optimization of the SREBP signaling assay
The reporter gene assay used in this study has been previously
described [18]. Briefly, this assay is based on endogenous SREBP-
mediated activation of a promoter containing three sterol
regulatory elements (SREs) driving the expression of a firefly-
luciferase gene (reporter construct, Figure 1A). As a transfection
control for the luciferase assays, a renilla-luciferase gene, driven by
a weak constitutive active SV-40 promoter, was co-transfected
along with the firefly-luciferase gene (Figure 1A). The activity of
the reporter gene assay was measured as a ratio between the firefly
and renilla luciferase levels. Thus, a high luciferase ratio indicates
SREBP pathway activation (due to a higher firefly luciferase levels)
and vice-versa. For our experiments, this SREBP signaling assay
was optimized by a series of steps. First, in order to use an optimal
reporter construct the 36SREs cassette was sub-cloned and tested
in a number of luciferase vectors including, pGL3-Basic and
pTransLucent. In our hands, the pTransLucent vector displayed
higher luciferase ratios and higher signal-to-noise ratio [48] in a
384-well format and was chosen for further experiments (data not
shown). Second, two mammalian cell lines HEK-293 and HeLa
were tested for cell line of choice. HEK-293 cells displayed higher
assay reproducibility, luciferase signals and fold change under
different experimental conditions and were thus chosen for this
study (data not shown). Third, a mutant SRE promoter [49]
driving a luciferase gene was generated and used as a specificity
control for our experiments. This mutant SRE-luciferase construct
was inactive under all experimental conditions (Figure 1B). Fourth,
to optimize the repression of SREBP signaling by cholesterol, a
concentration response curve for 25-hydroxy (25-OH) cholesterol
with varying times of incubation was performed. The result
showed that incubating cells with 1 mg/ml 25-OH cholesterol for
24 hours was sufficient to repress the assay as efficiently as using
5 mg/ml 25-OH cholesterol and hence the lower concentration
was used for further studies (Figure 1C).
We tested the robustness and sensitivity of the assay by
evaluating the effects of SCAP and INSIG1 overexpression on
SREBP signaling under normal cell culture conditions (cells
grown in medium containing 10% serum and antibiotics). Full-
length plasmids encoding hamster SCAP [18] and human INSIG1
[40] were co-transfected along with the wild-type SRE-luciferase
reporter and changes in luciferase ratios were measured. We
noted an approximate three and a half fold activation or
repression of basal (empty vector over-expression) SREBP
activity in the presence of SCAP or INSIG1, respectively
(Figure 1B). A dominant-positive form of SCAP (DP-SCAP)
which no longer binds INSIG1 as it contains a point mutation in
its INSIG1 interacting domain [24], was equally active in
enhancing SREBP signaling as wild-type SCAP. In addition, a
dominant negative form of SCAP (DN-SCAP) which lacks the
INSIG-binding domain [50], repressed SREBP cleavage as
efficiently as over-expression of INSIG1 (Figure 1D). Next, we
examined the effects of SCAP and INSIG1 over-expression in
the presence of high cholesterol (1 mg/ml 25-OH cholesterol).
The repressed luciferase levels found under high cholesterol
conditions were rescued by the over-expression of positive
components of the SREBP pathway such as wild-type SCAP or
DP-SCAP as expected (Figure 1D). Under these conditions of
repressed luciferase activity, we found no further measurable
inhibitory effects of INSIG1 (Figure 1D).
Genome-wide screen for regulators of cellular cholesterol
homeostasis
Having determined the optimal conditions for the SREBP
signaling assay, we made use of the sufficient fold difference under
normal cell culture conditions to identify novel activators and
repressors of the SREBP pathway. To this end, a collection of
10,000 random full-length human cDNAs was screened using a
‘gene-by-gene’ unbiased assay. The screen was carried out in
duplicate so that the data could be subjected to 2-dimensional (2D)
normalization i.e. normalization to remove both well-to-well and
plate-to-plate variation (see Materials and Methods for details). A
scatter plot for the primary screen was obtained by plotting the 2D
normalized luciferase ratios for a clone in the first experiment
against that obtained in the second experiment (Figure 2A). The
SREBP Activity Modifiers
PLoS ONE | www.plosone.org 2 April 2009 | Volume 4 | Issue 4 | e5197
clones lying at the extremities displayed highest activity and were
selected for further validation (circles). Clones which modulated
luciferase ratios by at least 2-fold were re-tested for their effects in
the SREBP signaling assay. With this cut-off, a total of 176
activators and repressors were selected for re-confirmation assays.
Each clone was assayed in triplicate for all the subsequent follow-
up experiments. The scatter plot of the total re-screening data
showed that the clones lie along the diagonal, indicating internal
consistency of the experimental conditions (Figure 2B). The first of
these experiments confirmed the behavior of each clone under
identical conditions to that used for the original gene-by-gene
unbiased screen. Furthermore, we found that genes identified in
the primary screen as activators (red) clustered separately from the
repressors (blue), confirming the reproducibility of the results
(Figure 2C). Clones showing no clear discrimination as either
activators or repressors were removed from final analysis
(Figure 2C, central overlapping red and blue points and Figure
S1). Genes that activated or suppressed SREBP cleavage to the
greatest extent were found at the extremities of the scatter plot.
We next utilized the mutant SRE-luciferase reporter to identify
non-specific regulators of SRE-luciferase. When compared to the
internal controls (colored central points), a set of genes that
significantly altered renilla levels (data not shown) and/or changed
mutant-SRE promoter activity (Figure 2D, extremities of the
scatter plot) were discarded as being false positives. Genes in the
activator set that did not affect the mutant SRE promoter were
deemed as candidates that regulate SREBP signaling (Figure 2D,
circled central grey points). Thus, starting from 176 clones this
analysis resulted in 27 activators and 40 repressors (Tables S1, S2)
that showed specific effects in regulating the SREBP assay (Figure
S1), while not affecting the mutant SRE promoter.
Gene set enrichment analysis (GSEA) of high throughput
screening data
Results from the primary gene-by gene screen were analyzed by a
novel application of the Gene Set Enrichment Analysis (GSEA)
technique modified for high throughput screening data (for details
see Materials and Methods). We identified a number of pathways
Figure 1. The SREBP cleavage assay. (A) Schematic representation of the SREBP cleavage assay. (B) Activity of wild-type (WT) versus mutant (Mut)
SRE promoter. HEK-293 cells were set up in a 96-well plate (in triplicate). After 24 hours, cells were transfected with either WT (open bars) or mutant
(black bars) luciferase reporter constructs, along with renilla luciferase construct and the indicated plasmid /cDNA. Cells were grown for an additional
24 hours before performing the assay. (C) Effects of 25-hydroxy cholesterol (25-OH chol.) on SREBP signaling. The assay was carried out under varying
25-OH cholesterol concentrations (0.1–5 mg/ml) and for different incubation periods (6, 12, and 24 hours). 25-OH chol. was added to cells 1 day after
transfecting with the reporter plasmids, SRE-luciferase and renilla luciferase. Maximum suppression of SRE-luciferase signals was observed after
24 hours of incubation with 25-OH chol (shown here). The effects of DP-SCAP under high 25-OH cholesterol levels are significantly higher at all
concentrations (Student’s t-Test, p,0.005). (D) Effects of known repressors, activators and high cholesterol (25OH chol., 1 mg/ml) on the SREBP
signaling pathway. The assay was carried out as in B. Basal refers to pcDNA3 overexpression. SCAP and DP-SCAP significantly activate the assay in the
absence (white bars) or presence (black bars) of 25-OH cholesterol (Student’s t-Test, p,0.05). (B–D) Error bars indicate standard deviations (n = 3).
Where not visible, error bars are smaller than symbols. The graphs are representative of at least 2 independent experiments.
doi:10.1371/journal.pone.0005197.g001
SREBP Activity Modifiers
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whose members coordinately modulate SREBP activity as measured
in this screen. The GSEA results included pathways which are
known to positively regulate intracellular cholesterol homeostasis,
such as polyunsaturated and unsaturated fatty acid biosynthesis
(Figure 3B) and sphingolipid metabolism pathways, as well as the
nuclear hormone receptor pathway (Table 1). Additionally, signaling
pathways relating to heterotrimeric G-proteins, small GTPases
(including the Rab family of GTPases), RAS- and RAS-related
GTPases and angiotensin signaling via PYK2, all of which have been
implicated in the regulation of intracellular cholesterol metabolism
(see discussion), were identified as activators of SREBP signaling. We
also identified pathways previously not associated with the regulation
of lipid homeostasis including ephrin signaling and epidermal growth
factor receptor (EGFR) signaling pathways. In contrast to the
identified activators, a majority of which impacted intracellular
signaling events, the repressors from our screen were enriched for
pathways associated with the extracellular matrix, cell adhesion &
cell matrix interactions (Figure 3C) and matrix glycoproteins
(Table 2). Proteins regulating the cytoskeleton and cell architecture
and serine proteases were also found to repress the cholesterol
pathway.
Application of a GSEA variant [51], the Levene test for
homogeneity of variance as modified by Brown and Forsythe
(LBF), [52] identified several pathways that included both positive
and negative regulators of cholesterol homeostasis. The significant
pathways identified once again included known regulators of
cellular cholesterol homeostasis such as lipid metabolism, regula-
tion of metabolism and Ras pathways as well as novel pathways
such as Gap junction (Figure 3D), B-cell receptor and the Slit-
Robo signaling pathways (Table 3). Notably, our screening results
suggest a reciprocal relationship between gap junction formation
and cholesterol homeostasis (see discussion and Table S3).
Novel modifiers of SRE-luciferase act by stimulating or
repressing SREBP activity
To further understand the influence of the candidate genes on
regulating SREBP signaling, we tested the activators in the
Figure 2. Primary and secondary screen results. (A) Scatter plot showing the result from the primary screening of 10,000 putative full-length
human cDNA’s in the SREBP cleavage assay. The 2D-normalized z-scores for a clone in the first experiment (x-axis) are plotted against that obtained in
the second experiment (y-axis). Genes at the top right corner represent potential activators of SREBP signaling, while those at the bottom left corner
represent potential repressors of SREBP signaling (circles). (B) Scatter plot representing the combined data from all secondary screens. Each clone was
re-tested in triplicate in two separate experiments. Firefly to renilla luciferase ratios for a clone in the first experiment (x-axis) were plotted against the
ratios for the same clone in the second experiment (y-axis). (C) Analysis of the selected 176 clones under conditions identical to those used in the
primary screen. Scatter plot shows luciferase ratios obtained for a clone in the first experiment against ratios obtained for the same clone in the
second experiment. Activators are represented in red and repressors in blue. Circles represent clones displaying the highest activation or repression
of luciferase ratios. (D) Effect of the 176 selected activators and suppressors (grey points) on mutant SRE promoter. The scatter plot shows the
luciferase ratios obtained for a clone in the first experiment against luciferase ratios obtained in the second experiment. Central data points (circle)
represent genes that did not have an effect on the mutant SRE-luciferase. Grey points falling at the extremities represent clones that activated the
mutant SRE-luciferase or had higher levels of renilla luciferase. Control genes are color coded as: red, DN-SCAP; dark blue, DP-SCAP; yellow, INSIG1;
black, SCAP; green, pSport6; sky blue, pXL4; pink, pcDNA3.
doi:10.1371/journal.pone.0005197.g002
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presence of excess sterol (1 mg/ml 25-OH cholesterol). As shown
in Figure 4A, under high 25OH-cholesterol conditions, a majority
of the genes identified as activators in our screen were clustered in
the bottom left corner of the scatter plot indicating that the activity
of these genes was attenuated in the presence of excess cholesterol.
In contrast, we found only one gene (shown in triplicate) that was
able to overcome high cholesterol levels (Figure 4A). This clone
corresponded to sterol regulatory element binding protein 1c
(SREBP1c).
In addition to excess cholesterol, we also tested the activators in
the presence of high INSIG1 levels to probe whether any of the
genes in the activator set could overcome INSIG mediated
pathway inhibition. As expected, co-overexpression of SCAP was
found to overcome INSIG1-mediated SREBP stabilization. Of the
27 novel genes (Table S1) that promoted SREBP signaling, ten
new genes were identified that were able to overcome the
inhibitory effects of INSIG1 in a manner similar to that of SCAP,
under conditions of excess INSIG1 (Figure 4B and 4C). These
genes include bridging integrator-1 (BIN1), GLI-Kruppel family
member, HKR3 (HKR3), high-mobility group box 3 (HMG3), the
hypothetical protein FLJ25477, myelin basic protein (MBP),
phospholipase C, beta 1 (PLCB1), podocalyxin-like 2 (PODXL2),
RAP2B member of RAS oncogene family (RAP2B), kruppel-like
factor 11 (KLF11) and sorting nexin 8 (SNX8).
Activation of SREBP cleavage by over-expression of SCAP can
be repressed by co-overexpression of INSIG1 [40]. To examine if
any of the 40 novel repressors could exert a similar effect as
INSIG1, candidate repressors were tested for their ability to down-
regulate elevated luciferase ratios resulting from SCAP overexpres-
sion. INSIG1 and DN-SCAP could down-regulate SCAP induced
SREBP signaling (Figure 5A, yellow and red points respectively)
and served as controls. Interestingly, a number of candidate genes
(grey points) localizing with INSIG1 (yellow points) in the bottom
left corner of the scatter plot were identified (Figure 5A), indicating
these genes effectively repressed SREBP signaling despite SCAP
over-expression. Eight genes repressed SCAP mediated activation
of SREBP signaling as efficiently as INSIG1 (Figure 5B). These
included bone morphogenetic protein 1 (BMP1), DEAD box
polypeptide 28 (DDX28), lymphotoxin beta receptor (LTBR),
mannan-binding lectin serine peptidase 2 (MASP2), N-acetyl-
glucosaminidase, alpha (NAGLU), sortilin-related VPS10 domain
containing receptor 1 (SORCS1), thyrotropin-releasing hormone
degrading enzyme (TRHDE) and BTG3 associated nuclear protein
(BANP).
To rule out the possibility that the effects of the novel genes
identified in this screen are due to variations in transfection-
control renilla luciferase levels, we have analyzed these values
separately. We observe about a 2-fold variation in renilla luciferase
values across the samples (Tables S1, S2). We believe that this
variation is to be expected for a transient transfection experiment
and does not influence the outcome of the luciferase assays
significantly. The only cases where we have noticed the renilla
luciferase values to be low are for the hypothetical protein
FLJ25477 and RAP2B (Table S1).
Discussion
Starting with a gene-by-gene approach to screen for modifiers of
SRE-luciferase activity, we have identified several known and
novel modulators of SREBP transcriptional activity.
With the aim of identifying novel activators of SREBP activity,
we tested the primary hit list in the presence of high cholesterol
and INSIG1 co-overexpression. Only one gene (SREBF1) was able
to overcome these repressive conditions (Figure 4A and 4B). The
activation of the SRE-luciferase reporter by SREBF1 even in the
presence of sterols is most likely due to the production of the
cleaved N-terminal transcriptional activator [14] . However, in the
presence of INSIG1 co-overexpression, we identified ten novel
genes that could overcome the inhibitory effects of INSIG1
(Figure 4C). Our finding that KLF11 and HMG3 act as SREBP
modulators is in keeping with previous studies implicating these
two classes of transcription factors in SREBP modulation [53–55].
Intriguingly, MBP, an integral component of myelin also activates
SREBP signaling. A recent study implicates SREBP-1c and
SREBP2 in the regulation of lipid metabolism and modulation of
gene expression in Schwann cells, the myelinating cell of the
Figure 3. Gene set enrichment results. Distribution of 2D
normalized z-scores (NZ2D) for (A) all cDNA clones used in this screen
and clones assigned to the (B) N-3,6 Polyunsaturated fatty acid
biosynthesis, (C) Cell Adhesion / Cell Matrix Interaction and (D) Gap
Junction pathways. The rightward shift of NZ2D scores among fatty acid
synthesis genes (B) relative to background (A) indicates that
overexpression of genes in this pathway on balance tend to activate
SREBP transcriptional activity, whereas the leftward shift in (C) indicates
that the cell adhesion/cell matrix tend to inhibit SREBP transcriptional
activity in this screen. Gap junction genes were spread on either side of
the median (D) indicating that a sub-set of gap junction genes activated
the SREBP pathway, while others repressed it.
doi:10.1371/journal.pone.0005197.g003
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Table 1. List of pathways designated as activators of SREBP signaling by Wilcoxon test.
Pathway name Pathway source Probestes Wilcoxon p-value Wilcoxon FDR q-value
Hyperplasia MetaCore 14 2.80E-05 0.012
Tyrosine protein kinase PANTHER 52 3.04E-05 0.012
n-3,6 Polyunsaturated fatty acid biosynthesis MetaCore 14 1.11E-04 0.018
Angiotensin signaling via PYK2 MetaCore 38 1.74E-04 0.023
G-protein PANTHER 118 2.16E-04 0.023
Epidermal cell differentiation MetaCore 64 2.21E-04 0.023
Ephrins signaling MetaCore 46 2.44E-04 0.023
Sphingolipid metabolism MetaCore 17 2.50E-04 0.023
Unsaturated fatty acid biosynthesis MetaCore 11 3.30E-04 0.027
T-cell activation PANTHER 53 3.43E-04 0.027
Small GTPase PANTHER 97 3.96E-04 0.028
Pancreatic neoplasms MetaCore 111 4.28E-04 0.029
Lupus erythematosus, systemic MetaCore 38 4.37E-04 0.029
Pituitary diseases MetaCore 17 4.45E-04 0.029
Immunoglobulin receptor family member PANTHER 37 5.07E-04 0.032
RAS-related GTPase PANTHER 55 5.47E-04 0.033
Neoplasms, complex and mixed MetaCore 38 5.49E-04 0.033
Nuclear hormone receptor PANTHER 20 6.27E-04 0.035
Axon guidance KEGG 87 6.75E-04 0.036
EGFR signaling via small GTPases MetaCore 24 7.03E-04 0.036
Ras-GDP/GTP PANTHER 6 9.56E-04 0.040
Non-receptor tyrosine protein kinase PANTHER 21 9.84E-04 0.040
EGF signaling pathway MetaCore 39 1.03E-03 0.040
RAC1 in cellular process MetaCore 18 1.16E-03 0.044
Transcription factor Tubby signaling pathways MetaCore 22 1.28E-03 0.048
doi:10.1371/journal.pone.0005197.t001
Table 2. List of pathways designated as repressors of SREBP signaling by Wilcoxon test.
Pathway name Pathway source Probestes Wilcoxon p-value Wilcoxon FDR q-value
Extracellular matrix PANTHER 136 2.97E-06 0.006
Cell adhesion_Cell-matrix interactions MetaCore 89 8.85E-06 0.009
Extracellular matrix glycoprotein PANTHER 41 1.84E-05 0.012
Skeletal development PANTHER 54 6.14E-05 0.017
Serine protease PANTHER 61 8.10E-05 0.017
Cell structure PANTHER 238 8.60E-05 0.017
Cytoskeletal regulation by Rho GTPase PANTHER 66 9.04E-05 0.017
Actin binding cytoskeletal protein PANTHER 191 2.38E-04 0.023
Proteolysis_Connective tissue degradation MetaCore 52 2.40E-04 0.023
Protocadherin alpha PANTHER 9 2.48E-04 0.023
Myosin PANTHER 31 3.52E-04 0.027
NF-kappaB cascade PANTHER 17 3.52E-04 0.027
Serine protease related PANTHER 25 6.23E-04 0.035
Microtubule family cytoskeletal protein PANTHER 97 7.15E-04 0.036
Cytoskeleton_Cytoplasmic microtubules MetaCore 71 7.42E-04 0.037
Urea cycle and metabolism of amino groups KEGG 10 1.02E-03 0.040
Synthetase PANTHER 41 1.03E-03 0.040
Proteolysis_ECM remodeling MetaCore 38 1.08E-03 0.042
doi:10.1371/journal.pone.0005197.t002
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peripheral nervous system [56]. Sorting nexin 8 (SNX8), another
novel activator of SREBP signaling is a member of a diverse family
of proteins that are grouped together based on the presence of a
phospholipid binding Phox-homology (PX domain) that impact
various intracellular trafficking and sorting events. Whether SNX8
regulates SREBP transcriptional activity by regulating intracellular
trafficking events remains to be evaluated.
In contrast, by co-overexpression of SCAP, we have identified
eight novel repressors of SREBP signaling (Figure 5B). Notably,
recent results suggest that the immune system, through LTBR
signaling, directly influences the enzymatic regulation of lipid
homeostasis [57], underscoring the potential value of the novel
modifiers identified in our screen. In addition, NAGLU is a
lysosomal enzyme involved in the degradation of heparin sulfate
[58]. Loss of NAGLU results in the lysosomal storage disease,
Sanfilippo syndrome type B [58,59]. SorCS1 is a type 1
transmembrane protein implicated in intracellular protein traf-
ficking and sorting and predominantly localized to neurons
[60,61] and it is tempting to speculate that SorCS1 might play a
role in lipid storage disorders of the brain. These novel repressors
may mediate their effect via direct / indirect regulation of SCAP,
via repressing SREBP transport or by modulating INSIG1 levels.
Further characterization and validation studies are needed to
distinguish between these possibilities and determine the precise
mechanism of action of the identified repressors and activators.
With an aim to elucidate pathways involved in the coordinate
control of SREBP signaling and cholesterol homeostasis we
analyzed primary results from the gene by gene screen using a
Gene Set Enrichment Analysis approach. In addition to known
regulators, this analysis unraveled novel roles for several pathways
including the ephrin receptor (EphR) and EGF receptor (EGFR)
signaling pathways, as putative activators or inhibitors of SREBP
signaling. Both EGFR and EphR have been shown to associate
with caveolin-1 positive microdomains [62,63] and signal via
cholesterol-rich lipid rafts, implying that these pathways might be
positively regulated by cellular cholesterol levels. Also, receptor
tyrosine kinases such as EGFR and EphRs activate MAPK
signaling which has been shown to stimulate SREBP transcrip-
tional activity [64]. Signaling via the transcription factor Tubby
represents another novel positive regulator of cholesterol homeo-
stasis identified in our screen (Table 1). Tubby has been shown to
bind to plasma membrane phophoinositides and participate in
heterotrimeric G-protein coupled receptor signaling (GPCR) and
there is ample evidence in support of a crucial role for cholesterol
Table 3. List of SREBP pathway modulators by LBF test.
Pathway name Pathway source Probestes LBF p-value LBF FDR q-value
Gap junction KEGG 52 3.00E-07 1.12E-04
Ras PANTHER 8 9.81E-07 2.75E-04
Long-term depression KEGG 32 1.38E-06 3.09E-04
Lipid metabolism PANTHER 78 2.02E-06 4.11E-04
Zinc finger protein PANTHER 19 3.77E-06 6.49E-04
Neoplasms, fibrous tissue MetaCore 26 6.79E-06 1.01E-03
Neoplasms, connective and soft tissue MetaCore 144 3.39E-05 4.22E-03
Cell adhesion_Platelet-endothelium-leucocyte interactions MetaCore 76 5.22E-05 6.15E-03
Autoimmune diseases MetaCore 189 5.58E-05 6.25E-03
Mucinoses MetaCore 12 7.72E-05 8.23E-03
Plasmacytoma MetaCore 60 8.87E-05 9.03E-03
Blood protein disorders MetaCore 63 9.47E-05 9.22E-03
B-cell- and antibody-mediated immunity PANTHER 33 1.21E-04 1.13E-02
Multiple myeloma/paraproteinemias MetaCore 58 1.57E-04 1.15E-02
Hemorrhagic disorders MetaCore 104 1.44E-04 1.15E-02
Anterior/posterior patterning PANTHER 22 1.59E-04 1.15E-02
Mesoderm development PANTHER 221 1.66E-04 1.16E-02
Neuroendocrine tumors MetaCore 207 2.00E-04 1.32E-02
B cell receptor signaling pathway KEGG 34 2.18E-04 1.36E-02
Macrophage-mediated immunity PANTHER 46 2.65E-04 1.60E-02
Regulation of metabolism MetaCore 135 3.64E-04 2.09E-02
Cell adhesion_Attractive and repulsive receptors MetaCore 125 4.89E-04 2.70E-02
Slit-Robo signaling MetaCore 29 5.06E-04 2.70E-02
Interleukin signaling pathway PANTHER 66 4.96E-04 2.70E-02
Arachidonic acid production MetaCore 7 7.20E-04 3.75E-02
Segment specification PANTHER 31 8.43E-04 4.20E-02
Sarcoma MetaCore 116 8.91E-04 4.29E-02
Vascular hemostatic disorders MetaCore 73 9.01E-04 4.29E-02
Carcinoma, neuroendocrine MetaCore 27 1.11E-03 4.87E-02
doi:10.1371/journal.pone.0005197.t003
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in modulating GPCR function (reviewed in [65]). It is worth
noting that recent studies have also unraveled a novel role for
tubby in regulating a Rab-dependent endocytic trafficking
pathway [66]. Enrichment for serine proteases as gathered from
our GSEA results indicates that in addition to the critical S1P/S2P
mediated cleavage of SREBP, and PCSK9 catalyzed LDLR
trafficking [67,68], additional important nodes in the SREBP
signaling pathway might be regulated by proteases. Also, the
notion that efficient and directional intracellular trafficking of
vesicles is closely dependent on microtubule and cytoskeleton
dynamics is supported by our analysis where we have identified
associated pathways as modifiers.
Finally, using a series of biological validation assays we
successfully matched number of GSEA significant pathways to
the genes identified in our screen (Table 4). It is worth noting that
the genes validated in this study, namely the activators RAB20,
RAB8A and BIN1 [69,70] and the repressors, SNX8 [71,72] and
SorCS1 [60] have all been implicated in membrane and vesicle
trafficking events. Interestingly, a recent gene expression profiling
comparison of normal and Niemann Pick disease type C (NPC)
patient fibroblasts revealed changes in several genes important for
membrane traffic including RAB20 and SorCS1 [73]. The LBF
GSEA analysis additionally points to a potential link between gap
junction formation and cholesterol homeostasis (Table S3). Our
screening results indicate that growth factors [74], protein kinase
A, and protein kinase C [75–77] signaling cascades that dampen
the formation and/or function of gap junctions also induce
SREBP activity. Conversely, microtubule related tubulins involved
in hemichannel transport [78], and casein kinases which promote
the formation of gap junctions [75,77,79] , inhibit SREBP activity
in our screen. Taken together, these results suggest a reciprocal
relationship between gap junction formation and cholesterol
Figure 4. Novel activators of the SREBP pathway. (A) Effects of activator genes in presence of 25-OH cholesterol. The cDNA’s were assayed in
the presence of 1 mg/ml 25-hydroxy cholesterol. Scatter plot shows the luciferase ratios obtained for a clone in the first experiment against that
obtained in the second experiment. Data points lying at the bottom left corner of the scatter plot represent genes that do not activate SRE-luciferase
in the presence of high cholesterol. SCAP (black points), DP-SCAP (dark blue points) and SREBF1 overcome cholesterol repression (top right corner).
Empty vectors color coded as: green, pSport6; sky blue, pXL4; pink, pcDNA3. (B) Effects of INSIG1 overexpression (15 ng/well) on novel activator
genes. SCAP (central black points), DP-SCAP (dark blue points) and SREBF1 (top right corner) escape repression by INSIG1. In addition, a number of
candidate genes (grey points) activated SRE-luciferase to a greater extent than SCAP. Colored points represent empty vectors: green, pSport6; sky
blue, pXL4; pink, pcDNA3. (C) Graphical representation of the ten novel activator genes that activate SREBP signaling under high INSIG1 levels. These
genes activate the SREBP signaling assay to a significantly greater extent than SCAP (Student’s t-Test, p,0.005 or p,0.05).
doi:10.1371/journal.pone.0005197.g004
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biosynthesis that may warrant further investigation. The novel
genes and pathways identified in the screen and subsequent
pathway analysis detailed in this study, when validated in disease
relevant contexts could represent novel therapeutic entry points or
pathway nodes that enhance our understanding of lipid biology.
Materials and Methods
Reporter constructs
Three copies of the sterol regulatory element (SRE, AAAAT-
CACCCCACTGCAAACTCCTCCCCCTGC) from the low-
density lipoprotein receptor gene promoter [18] were subcloned
upstream of a pTransLucent (Panomics) and pGL3-Basic
(Promega) luciferase vector to create a SRE-luciferase plasmid.
As a control, a mutated version of this promoter was synthesized
(Medigenomics) to contain four point mutations in each SRE
element as previously reported [49] (AAAAGAACCCCTATG-
CAAACTCCTCCCCCTGC, mutations underlined). As an
internal transfection normalization control, a humanized renilla
luciferase gene driven by a weak ubiquitous SV-40 promoter
(phRL-SV40, Promega) was used.
Plasmids and human cDNA clone collection
The cDNA used as controls for the SREBP cleavage assay,
namely full length hamster SREBP-cleavage activating protein
(SCAP), human INSIG1, hamster dominant positive and domi-
nant negative SCAP (DP-SCAP/DN-SCAP) have been previously
described [18,40,50,80]. For the genome-wide study, approxi-
mately 10,000 full-length cDNA clones were purchased from
OriGene Technologies (Rockville, MD) and prepared for
screening as previously described [81].
Cell lines and growth conditions
CHO wild-type and HEK-293 cells were obtained from ATCC.
The CHO wild-type and mutant cell lines were grown in F-12
(HAM) media (Invitrogen), supplemented with 5% new-born calf
serum (NCS), 10 mM HEPES buffer and 16 Penicillin-Strepto-
mycin (Invitrogen) antibiotic. HEK-293 cells were grown in
DMEM (Invitrogen) supplemented with 10% fetal bovine serum
(Invitrogen) and containing 16 Penicillin-Streptomycin (Invitro-
gen). All cell lines were grown in a humidified incubator at 37uC
and with 5% CO2. 25-hydroxy (25-OH) cholesterol (Sigma) was
dissolved added to media as indicated in figure legends.
Figure 5. Novel repressors of the SREBP pathway. (A) Effects of SCAP (15 ng/well) over-expression on novel repressor genes. Scatter plot
depicting the luciferase ratios obtained for a clone in the first experiment against ratios obtained in the second experiment. Internal control genes are
color coded as: yellow, INSIG1; red, DN-SCAP; green, pSport6; sky blue, pXL4; pink, pcDNA3. (B) Graphical representation of eight repressors that can
inhibit SCAP-mediated SREBP activation as efficiently as INSIG1 (Student’s t-Test, p.0.01).
doi:10.1371/journal.pone.0005197.g005
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Genome-wide cDNA study and luciferase assays
A reverse transfection protocol was followed for testing the
10,000 genes for their effect in the SREBP signaling assay.
Trypsinized HEK-293 cells were added to 384-well white opaque
bottom plates (Nunc), containing the cDNA clone and transfection
mix, at density of 2500 cells/well at 25 ml per well using a
Multidrop 384 (Thermo Labsystems) and incubated at 37uC in 5%
CO2. The transfection mix consisted of 17.5 ng reporter plasmid/
well, 0.7 ng Renilla/well and Fugene 6 (Roche) at a ratio of 3 ml
Fugene to 1 mg of DNA in 5 ml of Optimem (Invitrogen). The
transfection mixture was added to the 384-well plates containing
the cDNA clone using a FlexDrop (Perkin Elmer). The cDNA’s
were screened at a concentration of 120 ng/well. For cholesterol
stimulation, 25-hydroxycholesterol (Sigma) in 0.01% ethanol was
added to cells at a concentration of 1 mg/ml, and incubated for
24 hours. Firefly and Renilla luciferase activity was measured
40 hours post transfection using the Dual Glow assay system
(Promega). Plates were allowed to cool for 10 minutes before 30 ml
of each assay reagent was added. The plates were shaken for
10 minutes on a multi-plate shaker. Luminescence was determined
using an EnVision plate reader (Perkin Elmer) with a 100 msec
integration time. For luciferase assays carried out in 96-well plates,
all reagents were proportionally increased 4-fold.
Data analysis and 2D-normalization of genome-wide
study
Results were analyzed using Spotfire Decisionsite software and
Microsoft Excel. For the genome-wide study, luciferase ratios were
normalized as follows. The firefly-luciferase readout values were
first normalized using the corresponding renilla-luciferase readout
values. The firefly-renilla ratio was further normalized as follows.
The one-dimensional (1D) values were obtained by scaling the
ratios with the plate median in order to remove plate-to-plate
variation. The two-dimensional (2D) values were obtained by
further removing the well-to-well variations through an iterative
procedure. Finally, the normalized values were standardized to
obtain the NZ score, which is a more robust equivalent of the
more commonly used Z score. If the distribution is perfectly
normal, NZ score will be the same as the Z score.
GSEA methodology
Screening results were analyzed with a modified version of the
Gene Set Enrichment Analysis (GSEA) technique previously
described elsewhere [47,51,82]. As input, 2D normalized z-scores
(NZ2D) were first computed to estimate the effect of each cDNA
on the SREBP assay readout. NZ2D scores were averaged per
cDNA across replicates. These averaged NZ2D values were used
to rank the cDNAs for input to the GSEA method. Two variants
of the GSEA method were applied to these ranked scores. The first
method represented the standard GSEA approach [47,82] and
used the Wilcoxon ranked sum test [83] to identify pathways
whose members tended to activated or inhibited the assay. The
second GSEA variant applied a robust test for homogeneity of
variance [51], the Levene test as modified by Brown and Forsythe
(LBF) [52]. Application of the LBF test was used to identify
pathways that contain similar numbers of activators and repressors
of the assay. Such cases may elude detection by the Wilcoxon test,
as the contributions of activators and inhibitors tend to cancel each
other out. The presence of activators and inhibitors within a
pathway will yield a larger variance of NZ2D scores than is
generally present in the assay and is thus detectable by the LBF
test. Finally, a false discovery rate (FDR) [84] correction was
applied to the computed p-values to account for multiple
hypothesis testing. This process transforms the original p-values
into FDR q-values that were used for significance testing. The
GSEA results were then filtered to identify interesting pathways by
1) removing pathways with ,5 clones; 2) removing pathways with
.250 clones; 3) removing pathways with FDR q-values.0.05 for
the Wilcoxon and LBF tests. This resulted in 103 moderately-sized
pathways that had hits at q-values,0.05 in at least one test.
This application of GSEA is a natural extension of a
methodology that has enjoyed great success when applied to
microarray data [47,51,82]. Nevertheless, there are fundamental
differences between these types of experiments that impact the
interpretation of results. Whereas a simple microarray experiment
consists of a single perturbation and readouts for tens of thousands
of genes, this screen includes thousands of cDNA overexpression
perturbations and a single readout. When applied to microarray
data, GSEA identifies pathways that are modulated in response to
a specific perturbation. In this application, GSEA should identify
pathways that modulate SREBP activity. The recovery of several
pathways known to modulate cholesterol homeostasis validates the
application of pathway-centric methodologies for analyzing cDNA
overexpression screens.
Supporting Information
Figure S1 Scatter plot of the novel activators (red) and
repressors (blue) of SREBP signaling after removal of the false
positives and clones with high renilla luciferase levels.
Found at: doi:10.1371/journal.pone.0005197.s001 (1.31 MB TIF)
Table S1 Complete list of validated activators of SREBP
signaling.
Found at: doi:10.1371/journal.pone.0005197.s002 (0.04 MB
XLS)
Table S2 Complete list of validated repressors of SREBP
signaling.
Found at: doi:10.1371/journal.pone.0005197.s003 (0.04 MB
XLS)
Table S3 Genes that affect the formation and function of Gap
Junctions also modulate SREBP activity: Several branches of the
KEGG Gap Junction (HSA04540) pathway were notable for their
coordinate regulation of the SREBP assay. Notably, positive
Table 4. Overlap between GSEA and biological validation.
Pathway name from GSEA
Gene from biological
analysis




Serine protease LACTB, ABHD4, MASP2
n-3,6 Polyunsaturated & unsaturated fatty acid
biosynthesis
ACSL4
Arachidonic acid production ACSL4
G-protein, small GTPase & RAS-related GTPase RAB20, RAB8A, RAP2B
Neuroendocrine tumors BIN1, RAB8A
Lipid & sphingolipid metabolism SPTLC1, PLCB1
Autoimmune diseases MBP, SPTLC1
Cell structure & Gap junction CSNK1E, DGCR14, MBP
Novel genes regulating SREBP signaling that were identified in the biological re-
screens were mapped onto the pathway analysis data. Shown here are the
novel genes that showed up in both biological as well as pathway analyses.
doi:10.1371/journal.pone.0005197.t004
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regulators of gap junctions tended to inhibit SREBP activity (Casein
Kinases, Microtubules), whereas negative regulators tended to
activate SREBP (Growth Factors, Protein Kinase C, Protein Kinase
G). The most potent inhibitor and activator among these were
validated in secondary assays (PLCB1, CSNK1E). Some genes
showed isoform selectivity for SREBP activity, e.g. the epsilon
isoform of casein kinase 1 was a more potent activator than the delta
and gamma isoforms. Nevertheless, the consistency of results across
several independent branches of gap junction formation signaling
pathways suggests an inverse causal relationship between the
function of gap junctions and cholesterol homeostasis.
Found at: doi:10.1371/journal.pone.0005197.s004 (0.03 MBXLS)
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